melagatran has been researched along with Myocardial Infarction in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Christersson, C; Johnell, M; Siegbahn, A | 1 |
| Braunwald, E; Giugliano, RP | 1 |
| Falk, E; Hansson, GK; Hemdahl, AL; Thorén, P | 1 |
| Brighton, TA | 1 |
| Bylock, A; Christersson, C; Oldgren, J; Siegbahn, A; Wallentin, L | 1 |
| Fleischer, K; Gulba, DC; Lankes, W | 1 |
2 review(s) available for melagatran and Myocardial Infarction
| Article | Year |
|---|---|
The direct thrombin inhibitor melagatran/ximelagatran.
Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation; Glycine; Humans; Myocardial Infarction; Secondary Prevention; Stroke; Thrombin; Treatment Outcome; Venous Thrombosis | 2004 |
[Direct thrombin antagonists].
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Antithrombins; Arginine; Azetidines; Benzylamines; Fibrinolytic Agents; Glycine; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Rabbits; Recombinant Proteins; Sulfonamides; Syndrome; Thrombin; Thromboembolism; Thrombosis; Time Factors | 2001 |
1 trial(s) available for melagatran and Myocardial Infarction
| Article | Year |
|---|---|
Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction.
Topics: Aged; Azetidines; Benzylamines; Biomarkers; Blood Coagulation; Dose-Response Relationship, Drug; Female; Fibrin; Glycine; Humans; Male; Myocardial Infarction; Partial Thromboplastin Time; Pharmacokinetics; Thrombin; Time Factors | 2005 |
3 other study(ies) available for melagatran and Myocardial Infarction
| Article | Year |
|---|---|
The influence of direct thrombin inhibitors on the formation of platelet-leukocyte aggregates and tissue factor expression.
Topics: Antithrombins; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Blood Platelets; Cell-Derived Microparticles; Dabigatran; Gene Expression; Humans; Leukocytes; Myocardial Infarction; Platelet Activation; Platelet Aggregation; RNA, Messenger; Thromboplastin | 2010 |
Improving antithrombotic treatment in patients after myocardial infarction.
Topics: Azetidines; Benzylamines; Clopidogrel; Fibrinolytic Agents; Glycine; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome; Warfarin | 2003 |
Thrombin inhibitor reduces myocardial infarction in apoE-/- x LDLR-/- mice.
Topics: Animals; Apolipoproteins E; Azetidines; Benzylamines; Biomarkers; Coronary Artery Disease; Coronary Thrombosis; Electrocardiography; Glycine; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; Receptors, LDL; Thrombin; Troponin T | 2004 |